Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Gilead Sciences Begins Human Clinical Trials of Oral GS 840


Business Wire (03/04/94)

Foster City, Calif.--Gilead Sciences Inc. has begun Phase I human clinical testing to determine the safety, tolerance, and pharmacokinetics of its prodrug GS 840 in HIV patients. A prodrug is a modified version of a parent compound, designed to enhance the compound's delivery properties and convert to the parent compound once inside the body. GS 840 is a prodrug of Gilead's GS 393 compound, which is currently in ongoing Phase I/II clinical studies for HIV treatment. Preliminary findings from these trials indicate that administration of GS 393 is associated with reduced p24 antigenemia and transient increases in CD4 counts in selected AIDS patients. In addition, Gilead has two other products in human clinical trials. GS 504 is in Phase II/III pivotal trials for the potential treatment of peripheral retinitis caused by cytomegalovirus, a disease that can lead to loss of vision in AIDS patients. A topical formulation of GS 504 is being evaluated in Phase I/II studies as a potential treatment for herpes simplex virus infection.


Copyright © 1994 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in March 9, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.